Anthony P Adamis
Overview
Explore the profile of Anthony P Adamis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
6760
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hartnett M, Fickweiler W, Adamis A, Brownlee M, Das A, Duh E, et al.
Ophthalmol Sci
. 2024 Jul;
4(5):100521.
PMID: 39006804
Purpose: Hyperglycemia is a major risk factor for early lesions of diabetic retinal disease (DRD). Updating the DRD staging system to incorporate relevant basic and cellular mechanisms pertinent to DRD...
2.
Tumlinson A, Calara J, Azar D, Adamis A, Vavvas D, Stewart J
PLoS One
. 2024 Jan;
19(1):e0294526.
PMID: 38241211
Purpose: VitreoDx is an experimental device enabling push-button collection of a neat vitreous liquid biopsy incidental to an intravitreal injection. We explored the ability of the device to collect a...
3.
Adamis A, de Juan Jr E
Curr Opin Ophthalmol
. 2022 Mar;
33(3):131-136.
PMID: 35266895
Purpose Of Review: This review provides background on the remaining unmet needs with antivascular endothelial growth factor (VEGF) therapies for the treatment of neovascular age-related macular degeneration (nAMD). We also...
4.
Wykoff C, Abreu F, Adamis A, Basu K, Eichenbaum D, Haskova Z, et al.
Lancet
. 2022 Jan;
399(10326):741-755.
PMID: 35085503
Background: To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial...
5.
Holekamp N, Campochiaro P, Chang M, Miller D, Pieramici D, Adamis A, et al.
Ophthalmology
. 2021 Oct;
129(3):295-307.
PMID: 34597713
Purpose: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). Design: Phase 3, open-label, randomized, visual...
6.
Adamis A, Brittain C, Dandekar A, Hopkins J
Eye (Lond)
. 2020 Jun;
34(11):1966-1972.
PMID: 32541890
This article aims to identify key opportunities for improvement in the diagnosis and treatment of retinal disease, and describe recent innovations that will potentially facilitate improved outcomes with existing intravitreal...
7.
Campochiaro P, Marcus D, Awh C, Regillo C, Adamis A, Bantseev V, et al.
Ophthalmology
. 2019 Apr;
126(8):1141-1154.
PMID: 30946888
Purpose: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) treatment. Design: Phase 2, multicenter, randomized, active treatment-controlled clinical...
8.
Arcadu F, Benmansour F, Maunz A, Michon J, Haskova Z, McClintock D, et al.
Invest Ophthalmol Vis Sci
. 2019 Mar;
60(4):852-857.
PMID: 30821810
Purpose: To develop deep learning (DL) models for the automatic detection of optical coherence tomography (OCT) measures of diabetic macular thickening (MT) from color fundus photographs (CFPs). Methods: Retrospective analysis...
9.
Ferrara N, Adamis A
Nat Rev Drug Discov
. 2016 Jan;
15(6):385-403.
PMID: 26775688
The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA...
10.
Rubio R, Adamis A
Dev Ophthalmol
. 2015 Oct;
55:28-37.
PMID: 26502333
Systematic study of the mechanisms underlying pathological ocular neovascularization has yielded a wealth of knowledge about pro- and anti-angiogenic factors that modulate diseases such as neovascular age-related macular degeneration. The...